Plain-English translation of NCT04815096 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Researchers are studying how the body's immune system responds during COVID-19 recovery using a special imaging agent called [18F]F-AraG (VisAcT). This agent is injected into your bloodstream in a very small amount, and then a PET-CT scan shows where immune cells are active in your body. The goal is to understand the pattern of immune activation in people who have had COVID-19 to help develop better treatments.
Scientists don't yet fully understand how the immune system continues to respond weeks and months after COVID-19 infection. This study could help doctors better understand the recovery process and potentially identify new ways to support healing.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of a small amount of imaging agent, then wait about 50 minutes before undergoing a PET-CT scan of your whole body. This scan takes images to show where your immune system is active. You may be invited back for an optional second scan 1 to 12 months later. The study is based at a single medical center, and involves minimal radiation exposure.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States
Sponsor
CellSight Technologies, Inc.
Collaborators
University of California, San Francisco
Enrollment target
~80 participants
Started
April 2021
Primary completion
October 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Timothy Henrich, MD
University of California, San Francisco
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.